文献速递食管胃疾病与幽门螺杆菌肝病消化内镜

综述文章:慢性肝病中的食管疾病

Review article: Oesophageal disorders in chronic liver disease.
PubMed 文献 · Aliment Pharmacol Ther · 2024-07-31

本文综述了慢性肝病(包括肝硬化)与食管疾病(如胃食管反流病、巴雷特食管、食管癌、食管动力障碍和食管念珠菌病)之间的关系,评估了流行病学、病理生理学和治疗因素。综述指出这些食管疾病在肝硬化患者中普遍存在,加重疾病负担,且质子泵抑制剂等治疗需谨慎考虑。

要点

  • 胃食管反流病、巴雷特食管、食管癌、食管动力障碍和食管念珠菌病在肝硬化患者中普遍存在。
  • 质子泵抑制剂等常用治疗在肝硬化患者中需谨慎考虑,因潜在不良反应和药代动力学改变。
  • 肝硬化常见干预如食管静脉曲张套扎术可能加重食管疾病相关症状。

核心结论

  • 食管疾病在肝硬化中常见并增加疾病负担,因症状复杂和治疗风险需谨慎管理。
  • 质子泵抑制剂和其他治疗必须谨慎使用,因肝硬化干预可能加重症状。

研究设计与样本

  • 本文为综述,通过PubMed数据库检索关于食管疾病与慢性肝病(包括肝硬化)关系的文献,评估流行病学、病理生理学和治疗因素。

主要发现

  • 胃食管反流病、巴雷特食管、食管癌、食管动力障碍和食管念珠菌病等食管疾病在肝硬化患者中普遍存在,加重肝病负担。
  • 这些疾病具有多方面的症状和致病基础,对肝硬化患者构成重大挑战,需要仔细诊断和管理。
  • 质子泵抑制剂等常用治疗在肝硬化患者中需谨慎考虑,因潜在不良反应和药代动力学改变。
  • 肝硬化患者常见干预如食管静脉曲张套扎术可能加重食管疾病相关症状。

临床怎么用

  • 肝硬化患者中食管疾病的管理需要谨慎方法,因可能与药物相互作用及不良反应风险。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Oesophageal disorders and chronic liver disease are common worldwide and significantly impact quality of life. The intricate link between these conditions, including how oesophageal disorders like GERD, Barrett's oesophagus and oesophageal cancer affect and are affected by chronic liver disease, remains poorly understood. AIMS: To review the relationship between oesophageal disorders and chronic liver disease, evaluating epidemiology, pathophysiology and therapeutic factors. METHODS: We reviewed the literature on the relationship between oesophageal disorders and chronic liver disease, including cirrhosis, using the PubMed database RESULTS: Oesophageal disorders such as gastroesophageal reflux disease, Barrett's oesophagus, oesophageal cancer, oesophageal motor disorders and oesophageal candidiasis are prevalent among individuals with cirrhosis, exacerbating the burden of liver disease. These diseases have a multifaceted symptomatology and pathogenic basis, posing a significant challenge in cirrhotic patients that necessitates careful diagnosis and management. Additionally, therapies frequently used for these diseases, such as proton pump inhibitors, require careful consideration in cirrhotic patients due to potential adverse effects and altered pharmacokinetics. Managing oesophageal disorders in cirrhotic patients requires a cautious approach due to possible interactions with medications and the risk of adverse effects. Furthermore, symptoms associated with these conditions are often exacerbated by common interventions in patients with cirrhosis, such as band ligation for oesophageal varices. CONCLUSIONS: Oesophageal disorders are common in cirrhosis and increase the disease burden. These conditions require careful management due to complex symptoms and treatment risks. Proton pump inhibitors and other therapies must be used cautiously, as cirrhosis interventions can worsen symptoms.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Idalsoaga F, Díaz LA, Ayares G, et al. Review article: Oesophageal disorders in chronic liver disease. Aliment Pharmacol Ther. 2024. PMID: 39082463. doi:10.1111/apt.18193

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。